TISSUE CLICK LTD

Their core work

Tissue Click Ltd is a Brighton-based biotech SME specialising in tissue engineering, regenerative medicine, and cell-based biological models. Their work spans two distinct but related biomedical domains: in vitro disease modeling (as demonstrated in the CENSUS neurodegeneration project) and functional biomaterial scaffold development for orthopaedic repair (MEFISTO). In MEFISTO, they contributed to developing a 3D biofunctionalised meniscal scaffold designed to prevent knee osteoarthritis following meniscectomy, integrating a personalised treatment algorithm to tailor clinical outcomes. Their value in EU consortia lies in bridging laboratory-scale tissue biology with cost-efficient translational manufacturing.

What they specialise in

How they've shifted over time

Their earliest H2020 involvement (CENSUS, 2016-2019) placed them in a neuroscience context — building cell-based models to study and screen against neurodegeneration, a research-tool-oriented role with no product at its endpoint. By 2019 they pivoted sharply toward applied orthopaedic tissue engineering in MEFISTO, with keywords anchored in 3D biofunctionalisation, meniscus regeneration, and cost efficiency — language that signals a move toward manufacturable, clinically deployable products. The trajectory is clear: from research-service provider in disease modeling to product-oriented biomaterial developer targeting a specific surgical indication.

Tissue Click is moving from upstream research tools (disease models) toward clinically translatable biomaterial products — a direction that positions them as a potential technology provider to medical device companies and surgical teams, rather than purely an academic research partner.

How they like to work

Tissue Click has never led an H2020 project, always joining as a specialist participant — a pattern consistent with a small, technically focused SME that plugs a specific biological or manufacturing capability gap in larger consortia. Across just two projects they accumulated 17 unique partners in 10 countries, suggesting they are placed in moderately large consortia rather than lean bilateral collaborations. The absence of repeated partners (visible across only 2 projects) makes loyalty patterns impossible to assess, but the breadth of national coverage implies comfort operating in multi-partner, multi-country teams.

Tissue Click has collaborated with 17 distinct organisations across 10 countries from just two projects, indicating consistent placement in mid-to-large international consortia. Their network is pan-European in scope, and the UK base combined with EU project participation signals cross-border operating capability despite post-Brexit complexity.

What sets them apart

Tissue Click occupies an unusual dual-domain space: they have demonstrated credibility in both neural cell modelling and orthopaedic tissue engineering — two fields that rarely share the same SME partner. This cross-domain biological fluency makes them a flexible specialist for consortia that need hands-on tissue engineering expertise combined with awareness of clinical translation constraints (the MEFISTO cost efficiency keyword is telling). For consortium builders, they offer the practical biomaterial and cell-biology execution capacity that academic partners often lack, at SME cost levels.

Highlights from their portfolio

• MEFISTO
  Their largest and most recent project (EUR 401,250, 2019-2024), MEFISTO is directly product-oriented — a 3D biofunctionalised meniscal scaffold with a personalised treatment algorithm, making it the clearest window into their applied biomedical manufacturing capability.
• CENSUS
  CENSUS (2016-2019) demonstrates an earlier, distinct competency in neurodegeneration cell modelling, showing that Tissue Click's biological expertise extends beyond orthopaedics into CNS disease research.